ArticleJournal of functional biomaterials2026
Partially Demineralized Acellular Bovine Bone Matrix Supports for Bone Healing In Vivo.
Article in Journal of functional biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acellular bone matrix, with its natural extracellular matrix components, has been considered a potential alternative platform for bone grafting. Our study focused on fabricating acellular bovine bone matrix (ABBM) and evaluating its in vitro characteristics and in vivo effect on bone repair. The bovine cancellous bone was subjected to ABBM preparation, which included partial demineralization and decellularization processing. The effects of the ABBM on human bone marrow-derived stem cells (hBMSCs) were evaluated, including viability, migration, attachment, and proliferation. A rabbit bone defect model was implanted with ABBM and histologically assessed for bone healing. The acellular properties were determined by the absence of nuclear material and the accepted minimum residual DNA content. An in vitro study indicated the ABBM's positive effect on the migration of hBMSCs. ABBM was also demonstrated to support hBMSC attachment and proliferation. In vivo testing was performed in rabbits with a cranial bone defect, which showed complete bone healing after 8 weeks of grafting with ABBM. Overall, the fabricated ABBM demonstrated in vitro and in vivo biocompatibility and effective support for bone healing in vivo, and therefore represents a potential xenogeneic biomaterial for bone tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.